Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00762892 · ClinicalTrials.gov registry record · Phase 4
Raltegravir vs. Atazanavir in Combination With Truvada® for the Treatment of Antiretroviral naïve HIV Infected Patients
A Phase 4 study, sponsored by The University of Texas Health Science Center, Houston.
- Completed
- Registry status
- Phase 4
- Development phase
- 33
- Enrollment target
NCT00762892 is a Phase 4 study that has completed, run by The University of Texas Health Science Center, Houston. The registered enrollment target is 33 participants.
The verdict
NCT00762892, a Phase 4 study, has completed, sponsored by The University of Texas Health Science Center, Houston.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 33 participants
- Enrollment target
Study Summary
This is a pilot that will evaluate two regimens for treating HIV infected patients that haven't been on treatment before. HIV/AIDS patients may have an increased risk of myocardial infarction and antiretroviral therapy used may contribute to this. We will evaluate virological, immunological and cardiovascular effects of two HIV treatment regimens.
Interventions
- DRUG Raltegravir and truvada
- DRUG Atazanavir, Norvir and Truvada
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2009-01 |
| Est. Completion | 2013-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00762892
The ClinicalTrials.gov registry entry for NCT00762892 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The University of Texas Health Science Center, Houston, which has 732 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Raltegravir and truvada is the first listed.
NCT00762892 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00762892 about?
NCT00762892 is a clinical study titled "Raltegravir vs. Atazanavir in Combination With Truvada® for the Treatment of Antiretroviral naïve HIV Infected Patients". This is a pilot that will evaluate two regimens for treating HIV infected patients that haven't been on treatment before. HIV/AIDS patients may have an increased risk of myocardial infarction and antiretroviral therapy used may contribute to this. We will evaluate virological, immunological and card...
What is the current status of trial NCT00762892?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 33 participants. The study started on 2009-01. Estimated completion is 2013-01.
What interventions are being tested in trial NCT00762892?
The interventions under investigation include: Raltegravir and truvada (DRUG), Atazanavir, Norvir and Truvada (DRUG).
Who is sponsoring clinical trial NCT00762892?
This trial is sponsored by The University of Texas Health Science Center, Houston, which has 732 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.